Related references
Note: Only part of the references are listed.Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Scott A. Halperin et al.
LANCET (2022)
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
Fengcai Zhu et al.
CLINICAL INFECTIOUS DISEASES (2022)
Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
Wey Wen Lim et al.
LANCET MICROBE (2021)
Boosting immunity to COVID-19 vaccines
Jennifer A. Juno et al.
NATURE MEDICINE (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
Qian He et al.
EMERGING MICROBES & INFECTIONS (2021)
WHO International Standard for anti-SARS-CoV-2 immunoglobulin
Paul A. Kristiansen et al.
LANCET (2021)
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Robert H Shaw et al.
LANCET (2021)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu et al.
LANCET (2021)
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
Mine Durusu Tanriover et al.
LANCET (2021)
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Alejandro Jara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
Johan Normark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
Yaniv Lustig et al.
LANCET RESPIRATORY MEDICINE (2021)
Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality
Cesar Victora et al.
ECLINICALMEDICINE (2021)
An interactive web-based dashboard to track COVID-19 in real time
Ensheng Dong et al.
LANCET INFECTIOUS DISEASES (2020)
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu et al.
LANCET (2020)
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
Novel prime-boost vaccine strategies against HIV-1
Jean-Louis Excler et al.
EXPERT REVIEW OF VACCINES (2019)
Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
Kimia Kardani et al.
VACCINE (2016)
The prime-boost strategy: exciting prospects for improved vaccination
IA Ramshaw et al.
IMMUNOLOGY TODAY (2000)